The Journal of Heart and Lung Transplantation
Volume 21, Issue 2 , Pages 271-281 , February 2002

Risk factors for bronchiolitis obliterans: a systematic review of recent publications

  • Linda D Sharples, PhD

      Affiliations

    • Medical Research Council (MRC) Biostatistics Unit, University Forvie Site, Papworth Everard, Cambridge, United Kingdom
    • Transplant Unit, Papworth Hospital National Health Service (NHS) Trust, Papworth Everard, Cambridge, United Kingdom
    • Corresponding Author InformationReprint requests: Linda D. Sharples, MD, MRC Biostatistics Unit, University Forvie Site, Robinson Way, Cambridge CB2 2SR, UK. Telephone: 01223-330389. Fax: 01223-330388
    • ,
  • Keith McNeil (FRCAP)

      Affiliations

    • Transplant Unit, Papworth Hospital National Health Service (NHS) Trust, Papworth Everard, Cambridge, United Kingdom
    • ,
  • Susan Stewart (FRCPath)

      Affiliations

    • Transplant Unit, Papworth Hospital National Health Service (NHS) Trust, Papworth Everard, Cambridge, United Kingdom
    • ,
  • John Wallwork (FRCS)

      Affiliations

    • Transplant Unit, Papworth Hospital National Health Service (NHS) Trust, Papworth Everard, Cambridge, United Kingdom

Received 30 April 2001 ,Accepted 21 August 2001.

References 

  1. Burke CM, Theodore J, Dawkins KD, et al.  Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest. 1984;86:824–829
  2. El-Gamel A, Sim E, Hasleton P, et al.  Transforming growth factor beta (TGF-β) and obliterative bronchiolitis following pulmonary transplantation. Journal Heart Lung Transplant. 1999;18:828–837
  3. Cooper JD, Billingham M, Egan T, et al.  A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 1993;12:713–716
  4. Girgis RE, Tu I, Berry GJ, et al.  Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant. 1996;15:1200–1208
  5. Keller C, Cagle P, Brown R, Noon G, Frost A. Bronchiolitis obliterans in recipients of single, double and heart-lung transplantation. Chest. 1995;107:973–980
  6. Sundaresan S, Mohanakumar T, Smith MA, et al.  HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation. 1998;65(5):648–653
  7. Bando K, Paradis IL, Similo S, et al.  Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg. 1995;110:4–13
  8. Husain AN, Siddiqui MT, Holmes EW, et al.  Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 1999;159:829–833
  9. Wiebe K, Harringer W, Wahlers T, et al.  ATG induction therapy and the incidence of bronchiolitis obliterans after lung transplantation (does it make a difference?). Transplant Proc. 1998;30:1517–1518
  10. Kroshus TJ, Kshettry VR, Savik K, et al.  Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg. 1997;114:195–202
  11. Heng D, Sharples L, McNeil K, Stewart S, Wreghitt T, Wallwork J. Bronchiolitis obliterans syndrome (incidence, natural history, prognosis, and risk factors). J Heart Lung Transplant. 1998;17:1255–1263
  12. Norgaard MA, Andersen CB, Pettersson G. Does bronchial artery revascularisation influence results concerning bronchiolitis obliterans syndrome and/or obliterative bronchiolitis after lung transplantation?. Eur J Cardiothorac Surg. 1998;14:311–318
  13. Swanson SJ, Mentzer SJ, Reilly JJ, et al.  Surveillance transbronchial lung biopsies (implication for survival after lung transplantation). J Thorac and Cardiovasc Surg. 2000;119:27–38
  14. Quantz MA, Bennett LE, Meyer DM, Novick RJ. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,459 lung transplantations. J Heart Lung Transplant. 2000;19:473–479
  15. Opelz G, Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. The Collaborative Transplant Study. (see comments) N Engl J Med. 1994;330:816–819
  16. Smith MA, Sundaresan S, Mohanakuma T, et al.  Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg. 1998;116:812–820
  17. Jaramillo A, Smith MA, Phelan D, et al.  Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation. 1999;67(8):1155–1161
  18. Duncan SR, Paradis IL, Yousem SA, et al.  Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis. 1992;146:1419–1425
  19. Ettinger NA, Bailey TC, Trulock EP, et al.  Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis. 1993;147:1017–1023
  20. Keenan RJ, Lega ME, Dummer JS, et al.  Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation. 1991;51:433–438
  21. Kruger RM, Shannon WD, Arens MQ, Lynch JP, Storch GA, Trulock EP. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation. 1999;68:1272–1279
  22. Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant. 1996;15:881–887
  23. Speich R, Thumheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation. 1999;67:315–320
  24. Hohlfeld J, Niedermeyer J, Hamm H, Schafers HJ, Wagner TOF, Fabel H. Seasonal onset of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant. 1996;15:888–894
  25. Milne DS, Gascoigne AD, Ashcroft T, Sviland L, Malcolm AJ, Corris PA. Organizing pneumonia following pulmonary transplantation and the development of obliterative bronchiolitis. Transplantation. 1994;57:1757–1762
  26. Ueno T, Snell GI, Williams TJ, et al.  Impact of graft ischaemic time on outcomes after bilateral sequential single-lung transplantation. Ann Thorac Surg. 1999;67:1577–1582
  27. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The registry of the International Society for Heart and Lung Transplantation (seventeenth official report—2000). J Heart Lung Transplant. 2000;19:909–931
  28. McSherry C, Jackson A, Hertz MI, Bolman RM, Savik K, Reinsmoen NL. Sequential measurement of peripheral blood allogeneic microchimerism levels and association with pulmonary function. Transplantation. 1996;62:1811–1818

PII: S1053-2498(01)00360-6

The Journal of Heart and Lung Transplantation
Volume 21, Issue 2 , Pages 271-281 , February 2002

Article Tools